C4 Therapeutics will present preliminary data from the ongoing Phase 1/2 study of CFT1946, our novel BiDAC™ degrader in mutant BRAF V600 solid tumors, at the ESMO - European Society for Medical Oncology Congress being held September 13-17 in Barcelona. Learn more: https://bit.ly/3WnpgUq #ESMO24
Great opportunity! Looking forward to connecting!
Exciting news, C4 Therapeutics, Inc. Therapeutics team! Looking forward to hearing about the preliminary data on CFT1946 at ESMO 2024. Best wishes for a successful presentation! 🚀 #ESMO24
Very exciting and innovative, we look forward to hearing more!